Compare Cassava Sciences Inc (FLNA) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs JetBlue Airways Corporation — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while JetBlue Airways Corporation trades at $5.6 (market cap $2.07B). The key difference: JetBlue Airways Corporation is far larger — about 39× Cassava Sciences Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JBLU | |
|---|---|---|
Market Cap | $53.14M | $2.07B |
Sector | Health | Industrials |
52-Week High | $4.64 | $6.46 |
52-Week Low | $1.09 | $4.03 |
Enterprise Value | -$33.43M | $9.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
JetBlue (JBLU) trades at $5.525, up 3.66% today, but remains below the consensus price target of $5.12. The stock shows a neutral technical signal with mixed moving averages and oscillators. Fundamentally, JBLU faces challenges with negative net income margins and ROE, though it maintains a low P/S ratio of 0.22. Recent news highlights expansion at Fort Lauderdale and a new payment partnership, but earnings misses in Q4 2025 and Q1 2026 underscore ongoing profitability struggles amid high debt levels.
The outlook for JBLU is cautious due to persistent losses and elevated leverage, offset by cost initiatives and strategic growth. Risks include fuel price volatility and competitive pressures, while analyst sentiment is mixed with a majority hold rating. Investors should weigh turnaround potential against financial headwinds in a cyclical industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
